Petruski-Ivleva N, et al. - Experts utilized administrative claims data from Horizon Blue Cross Blue Shield of New Jersey from 2014 through 2017 to evaluate incidence rates of Fournier gangrene or necrotizing fasciitis of the perineum among individuals treated with a second-line antidiabetic drug, in order to assess the safety signal in a population of individuals with T2DM. Very low incidence rates of Fournier gangrene or necrotizing fasciitis was discovered. While no sign was noticed of an heightened risk among sodium-glucose cotransporter-2 inhibitors users in comparison with comparable individuals treated with other second-line antidiabetic medications, the small number of events gave wide confidence intervals.